Clinical Trials Browser

Hormone Receptor Positive Breast Carcinoma × Clear all

NCT04762979 2026-01-02

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Phase 2 Active not recruiting

Hormone Receptor Positive Breast Carcinoma

NCT04505826 2025-08-24

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Phase 1/2 Completed

Hormone Receptor Positive Breast Carcinoma